Generic Name: pembrolizumab
Brand Name: Keytruda
Manufacturer: Merck Canada
Therapeutic Area: Classical Hodgkin lymphoma
Indications: Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.
Manufacturer Requested Reimbursement Criteria1: Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.
Submission Type: Initial
Tumour Type: Lymphoma
NOC Status at Filing: Pre NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule1: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | December 10, 2020 |
| Call for patient/clinician input closed | February 05, 2021 |
| Clarification: - Patient input submission received from Lymphoma Canada | |
| Submission received | January 29, 2021 |
| Submission accepted | - |
| Review initiated | March 11, 2021 |
| Draft CADTH review report(s) provided to sponsor for comment | May 26, 2021 |
| Deadline for sponsors comments | June 04, 2021 |
| CADTH responses on draft review report(s) provided to sponsor | July 05, 2021 |
| Expert committee meeting (initial) | July 15, 2021 |
| Draft recommendation issued to sponsor | July 27, 2021 To July 29, 2021 |
| Draft recommendation posted for stakeholder feedback | - |